All In Biotech

Drug Trial Radar · NCT07400588

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Dec 1, 2025

Primary completion

Sep 18, 2026

Study completion Sep 18, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

Conditions

  • Obese
  • Obesity
  • Obesity Type 2 Diabetes Mellitus
  • Weight Loss

Interventions

  • AleniglipronDrug

    Drug aleniglipron administered orally

  • PlaceboDrug

    Drug placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and relationship of AEs/SAEsTime frame: Baseline to week 31
  2. Assessment of vital signsTime frame: Baseline to week 31
  3. Assessment of laboratory measuresTime frame: Baseline to week 31
  4. Assessment of Electrocardiograms (ECG)Time frame: Baseline to week 31

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Lake Forest, California

  • Research Site

    Lomita, California

  • Research Site

    Hazelwood, Missouri

  • Research Site

    Columbus, Ohio

  • Research Site

    Moncks Corner, South Carolina

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    DeSoto, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Mesquite, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Tomball, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.